Sphera Funds Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Sphera Funds Management’s Portfolio KERX Stock Details KERX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-311,600	Closed	-$1.66M	–	132
2016 Q3	$1.66M	Sell	311,600 -251,300	-45%	-$1.36M	0.27%	81
2016 Q2	$3.73M	Buy	+562,900	New	+$3.15M	0.97%	29
2015 Q4	–	Sell	-700,000	Closed	-$2.46M	–	148
2015 Q3	$2.46M	Buy	+700,000	New	+$4.69M	0.31%	80
2015 Q2	–	Sell	-230,000	Closed	-$2.93M	–	173
2015 Q1	$2.93M	Buy	230,000 +30,000	+15%	+$386K	0.3%	82
2014 Q4	$2.83M	Buy	+200,000	New	+$3.1M	0.48%	72

Other funds holding KERX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Sphera Funds Management's KERX Position: Q4 2016 in Review

Sphera Funds Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2016, closing a stake of 311,600 shares — an estimated $1.66M sold.

Sphera Funds Management first reported a position in KERX in Q4 2014 and held it in 5 quarters. The position peaked at $3.73M in Q2 2016. 123 funds tracked by Wall St. Rank hold KERX as of Q4 2016.

Sphera Funds Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
Sphera Funds Management sold 311,600 Keryx Biopharmaceuticals Inc shares in Q4 2016, an estimated $1.66M.
Sphera Funds Management first reported a position in Keryx Biopharmaceuticals Inc in Q4 2014 and held it in 5 quarters.
Sphera Funds Management's Keryx Biopharmaceuticals Inc position peaked at $3.73M in Q2 2016.
123 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2016.

Based on Sphera Funds Management's 13F filing for Q4 2016, filed 13 Feb 2017.